Risk of severe coronavirus infection (COVID-19) in patients with inflammatory rheumatic diseases

CONCLUSION: Patients with IRD, especially autoimmune diseases and patients treated with rituximab, may be at higher risk of severe pneumonia due to SARS-Cov 2, compared to the general population. More studies are needed to analyze this association further in order to help managing these patients during the pandemic.PMID:33722949 | DOI:10.3899/jrheum.200755

Source: J Rheumatol - March 16, 2021 Category: Rheumatology Authors: Javier Bachiller-Corral Alina Boteanu Maria Jesus Garcia-Villanueva Carlos de la Puente Marcelino Revenga M Consuelo Diaz-Miguel Ana Rodriguez-Garcia Jose Luis Morell-Hita Marta Valero Carmen Larena Maria Blazquez-Ca ñamero Carlos A Guillen-Astete Sandra Source Type: research